Market Access What rare disease commercialisation in Europe teaches us - a... Rare disease launches are the ultimate stress test for European commercialisation.
Market Access Biotech leaders: ‘They're shoving this industry into the arm... At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.
Market Access European biopharma at a crossroads If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.
Market Access Five Takeaways from JP Morgan Week 2026 JP Morgan Week may not have produced megadeals this year, but it still yielded plenty of food for thought. Here's five quick insights from San Fran.
Market Access US pharma MFN and tariff dynamics: What EU and UK leaders ne... Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.
Market Access How can biotech survive its funding winter? Some may argue that VCs and public markets have turned against biotech, but the reality is they have become much more sceptical.
News FDA ramps up its pushback against compounded GLP-1s In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
